TSS
NTLA icon

Two Sigma Securities’s Intellia Therapeutics NTLA Stock Holding History

Two Sigma Securities’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,108
Closed -$153K – 1976
2024
Q4 		$153K Buy
+13,108
New +$205K 0.02% 1045
2022
Q1 		– Sell
-2,006
Closed -$237K – 2375
2021
Q4 		$237K Buy
+2,006
New +$251K 0.01% 959
2021
Q3 		– Sell
-2,444
Closed -$396K – 1814
2021
Q2 		$396K Buy
+2,444
New +$190K 0.01% 799

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Securities's NTLA Position: Q1 2025 in Review

Two Sigma Securities sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 13,108 shares — an estimated $153K sold.

Two Sigma Securities first reported a position in NTLA in Q2 2021 and held it in 3 quarters. The position peaked at $396K in Q2 2021. 294 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

  • Two Sigma Securities reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Securities sold 13,108 Intellia Therapeutics shares in Q1 2025, an estimated $153K.
  • Two Sigma Securities first reported a position in Intellia Therapeutics in Q2 2021 and held it in 3 quarters.
  • Two Sigma Securities's Intellia Therapeutics position peaked at $396K in Q2 2021.
  • 294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on Two Sigma Securities's 13F filing for Q1 2025, filed 15 May 2025.